Article of the week: Monoclonal antibody therapy in multiple myeloma

This review discusses pre-clinical and clinical studies on the use of monoclonal antibodies in multiple myeloma, including agents which have been shown to have no activity against myeloma cells. It outlines various agents and their specific targets, focusing particularly on those agents with strong evidence in clinical trials.

This review highlights the benefits of immunotherapy and more specifically monoclonal antibodies, as their toxicity profiles and tolerability give them great potential in the maintenance setting. It also indicates potential new therapies with strong evidence in pre-clinical trials.

Download the review here: Monoclonal antibody therapy in multiple myeloma